Direkt zum Inhalt
Merck

325767

Sigma-Aldrich

Lanthan(III)-carbonat Hydrat

99.9% trace metals basis

Synonym(e):

Fosrenol, Lanthanum(3+) tricarbonate hydrate

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Lineare Formel:
La2(CO3)3·xH2O
CAS-Nummer:
Molekulargewicht:
457.84 (anhydrous basis)
EG-Nummer:
MDL-Nummer:
UNSPSC-Code:
12352302
PubChem Substanz-ID:
NACRES:
NA.23

Assay

99.9% trace metals basis

Form

powder

Zusammensetzung

Degree of hydration, 2-5

Eignung der Reaktion

reagent type: catalyst
core: lanthanum

Verunreinigungen

≤1500.0 ppm Trace Rare Earth Analysis

SMILES String

O.[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O

InChI

1S/3CH2O3.2La.H2O/c3*2-1(3)4;;;/h3*(H2,2,3,4);;;1H2/q;;;2*+3;/p-6

InChIKey

AFCUGQOTNCVYSW-UHFFFAOYSA-H

Piktogramme

Exclamation mark

Signalwort

Warning

Gefahreneinstufungen

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Zielorgane

Respiratory system

Lagerklassenschlüssel

11 - Combustible Solids

WGK

nwg

Persönliche Schutzausrüstung

dust mask type N95 (US), Eyeshields, Gloves


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Reiko Inoue et al.
Clinical and experimental nephrology, 23(6), 859-864 (2019-03-02)
This study aims to describe the regional variance in prescriptions for chronic kidney disease (CKD) medications and to analyze regional characteristics to identify the sources of these differences by utilizing the National Database of Health Insurance Claims, which provides more
Stefan P Schumacher et al.
Nephrology (Carlton, Vic.), 24(2), 221-226 (2018-02-27)
Hyperphosphataemia is associated with increased mortality and morbidity in end stage renal disease. Despite phosphate binder therapy, a large proportion of patients do not reach the treatment target. In five contemporary binders we explored the influence of pH and phosphate
Atsushi Yaguchi et al.
PloS one, 12(7), e0180430-e0180430 (2017-07-14)
The effects of PA21, a novel iron-based and non-calcium-based phosphate binder, on hyperphosphatemia and its accompanying bone abnormality in chronic kidney disease-mineral and bone disorder (CKD-MBD) were evaluated. Rats with adenine-induced chronic renal failure (CRF) were prepared by feeding them
Olivier Phan et al.
BioMed research international, 2015, 515606-515606 (2015-07-30)
Elevated serum phosphorus, calcium, and fibroblast growth factor 23 (FGF23) levels are associated with cardiovascular disease in chronic renal disease. This study evaluated the effects of sucroferric oxyhydroxide (PA21), a new iron-based phosphate binder, versus lanthanum carbonate (La) and sevelamer

Artikel

The prevailing strategies for heat and electric-power production that rely on fossil and fission fuels are having a negative impact on the environment and on our living conditions.

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.